Cassava Sciences, Inc. Rebrands As Filana Therapeutics, Inc. To Focus On Filamin A-Based Therapies For CNS Disorders

Cassava Sciences, Inc. has announced that it is rebranding as Filana Therapeutics, Inc., reflecting the company’s strategic focus on developing innovative therapies that target the filamin A protein for the treatment of central nervous system (CNS) disorders. The new name and corporate identity highlight Filana Therapeutics’ commitment to addressing conditions such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with the dysregulation or overexpression of filamin A. The company will begin trading on the Nasdaq Capital Market under the ticker symbol “FLNA” at market open on March 11, 2026.

Rick Barry, President and Chief Executive Officer of Filana Therapeutics, stated that the rebranding marks a new beginning for the company. He explained that growing evidence suggests filamin A plays a critical role in neuronal development, and that modulating this protein may offer a promising approach to treating CNS disorders, including TSC-related epilepsy. By centering the company’s identity on filamin A, Filana Therapeutics emphasizes its dedication to rigorous scientific research and to bringing new treatment options to patients and their families. The company has also launched an updated corporate website, which can be accessed at www.filanatx.com.

Tuberous Sclerosis Complex is a rare genetic disorder caused by mutations in the TSC1 or TSC2 genes, which affect the mechanistic target of rapamycin (mTOR) pathway and can result in tumor growth in multiple organs. Epilepsy is the most common health challenge among individuals with TSC, affecting 80% to 90% of patients. TSC-related epilepsy impacts approximately 45,000 people in the United States, with most patients experiencing their first seizures within the first year of life. Despite multiple approved treatments, over 60% of patients continue to experience seizures that are resistant to antiepileptic therapy, highlighting the urgent need for new therapeutic approaches.

Filana Therapeutics, Inc. is a biotechnology company focused on developing novel investigational therapies that modulate the filamin A protein for the treatment of CNS disorders, including TSC-related epilepsy, as well as other conditions linked to filamin A dysregulation or overexpression. The company is committed to advancing scientific discovery and developing innovative treatment options for patients with significant unmet medical needs.